Big pharma, Partnering, Pharma

Dainippon Sumitomo pharma partners with Edison for EPI-743 and EPI-589

Posted on 02 April 2013

Tags: , , ,

Edison Pharmaceuticals pharma partners with Dainippon Sumitomo, a big pharma company in a  research/development and commercialization agreement with  for the development of EPI-743 and EPI-589 in Japan.

Under the terms of the agreement, DSP will gain development and commercialization rights in Japan in exchange for Edison receiving $35 million in upfront and $15 million in R&D support.

In addition, Edison will be eligible to receive $10-35 million in development milestones per indication and up to $460M in commercial milestone payments as well as royalties on commercial sales.

The initial scope of the transaction includes both pediatric orphan inherited mitochondrial and adult central nervous system diseases.

Under the terms of the agreement, DSP will undertake activities required for development, approval, and commercialization of EPI-743 in Japan.

The work will initially focus on orphan pediatric mitochondrial disease.

Edison will retain 100% ownership and direct all research, clinical, and commercial development of EPI-743 and EPI-589 outside of Japan.

In addition, the pharma partners will collaborate on the research and development of EPI-589 with a focus on adult central nervous system disease.

Edison will use proceeds derived from the partnership to advance the late stage development and commercialization of EPI-743 for Leigh syndrome and Friedreich's ataxia, as well as to advance EPI-743 in other exploratory phase 2 trials for rare pediatric diseases with shared mitochondrial mechanisms.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on  Dainippon Sumitomo company profile, recent partnering, M&A and financing news and articles

Report: Partnering Deals and Alliances with Dainippon Sumitomo

Related report: Partnering Deals and Alliances with Big Pharma

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
a1banner300x150animgif